PRELIMINARY
CLINICAL TRIAL OF SHEN MIN NATURAL HAIR LOSS PRODUCTS REPORTS IMPRESSIVE
SUCCESS RATES IN WOMEN
More than nine in ten subjects taking the products in a six-month
double-blind, placebo controlled clinical trial report hair loss
improvement using Biotech¹s Shen Min product
Bangor,
Maine Important new findings from a preliminary clinical trial
of Shen Min™, a two-component herbal supplement designed to
reduce hair loss and promote healthy hair, were announced today.
Subjects who completed the clinical trial and took Shen Min demonstrated
statistical improvement over placebo groups in hair thickness, perceived
appearance, and hair loss improvement at both the three (3) and
six (6) month intervals.
Specifically,
more than nine-in-ten (92.3%) of the subjects that completed the
Shen Min clinical trial reported hair loss improvement. Additional
top-line findings of those subjects completing the clinical trial
include:
Perceived
Appearance: More than three-fourths (76.9%) of the subjects taking
Shen Min reported some level of improvement in their perceived appearance
compared to fourteen percent (14.3%) taking the placebo.
Thickness:
More than three-in-four subjects (77.0%) taking Shen Min reported
some level of improvement. Additionally, there were indications
that actual hair growth was attained but the Company is awaiting
a second trial to affirm those results.
Approximately
90% of the subjects taking Shen Min were "happy" or "extremely
happy" with the product. Two-thirds of subjects taking Shen
Min reported that they would continue to use the product while approximately
thirty percent (31%) were uncertain. More than six-in-ten subjects
taking Shen Min reported that they would recommend the product to
others.
About
the Clinical Trial: The prospective, randomized, double-blinded
placebo controlled clinical trial was conducted by Marshall-Blum,
LLC, for BioTech Corporation. The clinical trial, which surpassed
Institutional Review Board design requirements, was limited to women
between the ages 40-60. Twenty-six (26) and seven (7) subjects completed
the trial on product and placebo, respectively.
|